Tags

Type your tag names separated by a space and hit enter

Activity of a novel cyclic lipopeptide, CB-183,315, against resistant Clostridium difficile and other Gram-positive aerobic and anaerobic intestinal pathogens.
Antimicrob Agents Chemother. 2012 Jun; 56(6):3448-52.AA

Abstract

We evaluated the activity of CB-183,315 against Clostridium difficile, including strains that are resistant to fluoroquinolones and metronidazole and with elevated MICs to vancomycin as well as other Gram-positive intestinal pathogens. The MICs of CB-183,315 against all C. difficile isolates were ≤ 1 μg/ml. CB-183,315 had greater activity than vancomycin and metronidazole against C. difficile isolates and was more active than the comparators against vancomycin-resistant enterococcus (VRE). CB-183,315 also had excellent activity against methicillin-resistant Staphylococcus aureus (MRSA), other Clostridium spp., and Peptostreptococcus spp.

Authors+Show Affiliations

Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA. dsnydman@tuftsmedicalcenter.orgNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22391542

Citation

Snydman, D R., et al. "Activity of a Novel Cyclic Lipopeptide, CB-183,315, Against Resistant Clostridium Difficile and Other Gram-positive Aerobic and Anaerobic Intestinal Pathogens." Antimicrobial Agents and Chemotherapy, vol. 56, no. 6, 2012, pp. 3448-52.
Snydman DR, Jacobus NV, McDermott LA. Activity of a novel cyclic lipopeptide, CB-183,315, against resistant Clostridium difficile and other Gram-positive aerobic and anaerobic intestinal pathogens. Antimicrob Agents Chemother. 2012;56(6):3448-52.
Snydman, D. R., Jacobus, N. V., & McDermott, L. A. (2012). Activity of a novel cyclic lipopeptide, CB-183,315, against resistant Clostridium difficile and other Gram-positive aerobic and anaerobic intestinal pathogens. Antimicrobial Agents and Chemotherapy, 56(6), 3448-52. https://doi.org/10.1128/AAC.06257-11
Snydman DR, Jacobus NV, McDermott LA. Activity of a Novel Cyclic Lipopeptide, CB-183,315, Against Resistant Clostridium Difficile and Other Gram-positive Aerobic and Anaerobic Intestinal Pathogens. Antimicrob Agents Chemother. 2012;56(6):3448-52. PubMed PMID: 22391542.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Activity of a novel cyclic lipopeptide, CB-183,315, against resistant Clostridium difficile and other Gram-positive aerobic and anaerobic intestinal pathogens. AU - Snydman,D R, AU - Jacobus,N V, AU - McDermott,L A, Y1 - 2012/03/05/ PY - 2012/3/7/entrez PY - 2012/3/7/pubmed PY - 2012/9/14/medline SP - 3448 EP - 52 JF - Antimicrobial agents and chemotherapy JO - Antimicrob Agents Chemother VL - 56 IS - 6 N2 - We evaluated the activity of CB-183,315 against Clostridium difficile, including strains that are resistant to fluoroquinolones and metronidazole and with elevated MICs to vancomycin as well as other Gram-positive intestinal pathogens. The MICs of CB-183,315 against all C. difficile isolates were ≤ 1 μg/ml. CB-183,315 had greater activity than vancomycin and metronidazole against C. difficile isolates and was more active than the comparators against vancomycin-resistant enterococcus (VRE). CB-183,315 also had excellent activity against methicillin-resistant Staphylococcus aureus (MRSA), other Clostridium spp., and Peptostreptococcus spp. SN - 1098-6596 UR - https://www.unboundmedicine.com/medline/citation/22391542/Activity_of_a_novel_cyclic_lipopeptide_CB_183315_against_resistant_Clostridium_difficile_and_other_Gram_positive_aerobic_and_anaerobic_intestinal_pathogens_ L2 - http://aac.asm.org/cgi/pmidlookup?view=long&pmid=22391542 DB - PRIME DP - Unbound Medicine ER -